MorphoSys in-licenses first clinical compound from Xencor
This article was originally published in Scrip
In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.
You may also be interested in...
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.